Quest Partners LLC Has $282,000 Stock Holdings in Masimo Co. (NASDAQ:MASI)

Quest Partners LLC grew its stake in shares of Masimo Co. (NASDAQ:MASI) by 8,360.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,115 shares of the medical equipment provider’s stock after purchasing an additional 2,090 shares during the period. Quest Partners LLC’s holdings in Masimo were worth $282,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. NBC Securities Inc. raised its stake in Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 73 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 200 shares during the period. HHM Wealth Advisors LLC increased its stake in Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after purchasing an additional 125 shares in the last quarter. Finally, Lazard Asset Management LLC raised its holdings in Masimo by 5,730.0% during the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 573 shares during the last quarter. Institutional investors own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on MASI shares. BTIG Research lifted their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price target for the company in a research note on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Piper Sandler lifted their target price on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $167.00.

Masimo Stock Performance

Shares of MASI opened at $177.70 on Tuesday. The stock has a 50 day moving average of $143.48 and a 200 day moving average of $128.00. The company has a market capitalization of $9.51 billion, a price-to-earnings ratio of 122.55 and a beta of 0.97. Masimo Co. has a 12 month low of $91.60 and a 12 month high of $178.11. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $0.63 EPS. As a group, sell-side analysts forecast that Masimo Co. will post 4.04 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.